Literature DB >> 758109

Dilatation of the ductus arteriosus by prostaglandin E1 in aortic arch abnormalities.

M A Heymann, W Berman, A M Rudolph, V Whitman.   

Abstract

Infants with aortic arch interruption of juxtaductal coarctation of the aorta may depend on patency of the ductus arteriosus to provide adequate lower body perfusion. In many such infants the ductus arteriosus constricts after birth, resulting in severe heart failure, poor systemic perfusion and acidemia. We infused prostaglandin E1 (PGE1) at a rate of 0.05--0.1 microgram/kg/min into seven infants with aortic arch interruption and eight infants with coarctation. In one infant in each group the ductus arteriosus was already closed and did not reopen. In one infant with coarctation an adequate trial was not accomplished, and in another adequate pressure measurements were not obtained. Of the remaining 11, the ductus arteriosus was effectively dilated by PGE1 in 10 infants. This was evidenced by an increase in descending aortic blood pressures and a reduction in the pressure difference between the main pulmonary artery and descending aorta in six infants with aortic arch interruption and between ascending and descending aorta in four infants with coarctation. Lower body perfusion improved and left ventricular failure was improved. The infant who did not respond was 5 months old. There were no complications.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 758109     DOI: 10.1161/01.cir.59.1.169

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  26 in total

1.  Effectiveness of prostaglandin E1 in relieving obstruction in coarctation of the aorta without opening the ductus arteriosus.

Authors:  L Liberman; W M Gersony; P A Flynn; J J Lamberti; R S Cooper; T J Stare
Journal:  Pediatr Cardiol       Date:  2004 Jan-Feb       Impact factor: 1.655

2.  Modified Van Praagh's operation for interrupted aortic arch with severe subaortic stenosis in a neonate.

Authors:  K Matsui; H Kohno; M Hisahara; K Fukae; M Umesue; R Takahashi; Y Nishibayashi
Journal:  Surg Today       Date:  1992       Impact factor: 2.549

Review 3.  PROSTAGLANDINS IN CONGENITAL HEART DISEASE.

Authors:  M Sharma; M Sasikumar; S D Karloopia; B N Shahi
Journal:  Med J Armed Forces India       Date:  2011-07-21

4.  Pharmacological manipulation of the ductus arteriosus.

Authors:  E D Silove
Journal:  Arch Dis Child       Date:  1986-09       Impact factor: 3.791

Review 5.  Pharmacologic manipulation of the ductus arteriosus in the neonate: a physiologic basis and current state of the art.

Authors:  S K Sanyal; A Abu-Melha
Journal:  Indian J Pediatr       Date:  1988 Jan-Feb       Impact factor: 1.967

6.  Administration of E-type prostaglandins in ductus-dependent congenital heart disease.

Authors:  E D Silove
Journal:  Pediatr Cardiol       Date:  1982       Impact factor: 1.655

7.  Interrupted aortic arch: natural history and operative results.

Authors:  G Schumacher; R Schreiber; H Meisner; H P Lorenz; F Sebening; K Bühlmeyer
Journal:  Pediatr Cardiol       Date:  1986       Impact factor: 1.655

8.  Aneurysmal dilatation of ductus arteriosus during lipo-prostaglandin E1 therapy for diaphragmatic hernia.

Authors:  M Tohyama; A Baba; T Tsuno; K Aonuma; A Komiyama
Journal:  Eur J Pediatr       Date:  1993-11       Impact factor: 3.183

Review 9.  Forty-six years of patient ductus arteriosus division at Children's Memorial Hospital of Chicago. Standards for comparison.

Authors:  C Mavroudis; C L Backer; M Gevitz
Journal:  Ann Surg       Date:  1994-09       Impact factor: 12.969

10.  Response to prostaglandin E1 in neonates with intracranial arteriovenous malformation treated for suspected congenital heart disease.

Authors:  R F Covert
Journal:  Pediatr Cardiol       Date:  1994 Mar-Apr       Impact factor: 1.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.